AbbVie Buyer Allergan is not the right means for the stock


In the six years since the Abbvie split from Abbott Laboratories, the company has been heading for a cliff: the end of US patent security for its criminal substance Humira.

Sale of Humira, Treating Rheumatoid Arthritis and a Dozen Other Diseases, accounts for more than half of AbbVie's annual revenue. With the drug losing patent security in the United States in 2023, the company has been running for a short time to find out how to fill that hole hole.

Source link

Back to top button

mahjong slot